Novartis' Gleevec Cancer "Magic Bullet" Extends Life In GIST Patients
6/06/2011
Stomach cancer and gastronintestinal stromal tumors (GIST) can be an expensive disease to treat, but for approximately $5,000 a month Novartis AG's cancer pill Gleevec (imatinib) seems to extend the lives of patients with this type of gastrointestinal cancer over the long-term when taking the drug for three years after surgery...
Supplement Found To Improve Quality Of Life For Female Cancer Survivors
6/06/2011
A natural nutritional supplement, marketed for the last decade as a sexual aid, has been shown to significantly improve overall quality of life for female cancer survivors, according to researchers at Wake Forest Baptist Medical Center. The findings will be presented today at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago...
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced new data showing how the company's lead investigational compound, custirsen (OGX-011/TV-1011), may work with innovative therapies MDV3100 and heat-shock protein 90 (Hsp90) inhibitors to suppress prostate cancer cell survival and improve treatment outcomes...
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that data showing that the investigational agent ZALTRAP™ (aflibercept), also known as VEGF Trap, significantly improved survival in previously treated metastatic colorectal cancer patients will be presented at the ESMO World Congress on Gastrointestinal Cancer on June 25, 2011...
Screenings Appear Not To Reduce Risk Of Ovarian Cancer Death
6/06/2011
A University of Alabama at Birmingham study released today reports that ovarian cancer screenings do not reduce a woman's risk of death from the disease and the invasive medical procedures may create associated health problems...
Biopsy Needle Provides Advanced Accuracy In Diagnosing Cancers Of GI Tract
6/06/2011
Results from a multicenter European study[1] suggest that a new, large-core biopsy needle designed for use with an endoscopic ultrasound (EUS) scope may help to overcome limitations of current EUS methods for biopsies of lesions in the gastrointestinal (GI) tract and surrounding tissue...
Exelixis' Cabozantinib Demonstrates Broad Clinical Activity In Multiple Tumor Types
6/06/2011
Exelixis, Inc. (NASDAQ:EXEL) today reported updated interim data from an ongoing phase 2 adaptive randomized discontinuation trial (RDT) of cabozantinib in patients with advanced solid tumors...
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation (abstract #8013) at the ASCO 2011 Annual Meeting in Chicago...
Ipsen Announces Discontinuation Of The Development Of Irosustat In Monotherapy
6/06/2011
Ipsen (Paris:IPN) (Euronext: IPN - ADR: IPSEY) today announced its decision to assess the alternative development of Irosustat (BN 83495) in combination with other hormonal therapies...
Could a drug that is now used to treat a nerve cell condition and another prescribed to treat kidney cancer be combined to combat the deadliest form of skin cancer? That is the focus of research now underway at The Cancer Institute of New Jersey (CINJ), which aims to determine safe dosing levels for the drugs known as riluzole and sorafenib when used together in the treatment o...